Lung cancer includes a group of malignant epithelial tumors that originate
in the cells lining the lower respiratory tract and are the leading cause
of cancer-related deaths in the United States and worldwide. Lung cancer
is divided into two categories non-small cell lung cancer (NSCLC) and small
cell lung cancer. NSCLC accounts for more than 80% of all lung cancers,
and there are three major types of NSCLC (adenocarcinoma, squamous cell
carcinoma, and large cell carcinoma), which are further subtyped.
NSCLC is most common in older smokers and former smokers. Small tumors
in the lungs are usually asymptomatic, so most patients have locally advanced
or metastatic lesions at the time of diagnosis. The most common first symptoms
are cough, chest pain, hemoptysis, dyspnea, and weight loss.
Targeted therapies are available for patients with molecularly defined
NSCLC, such as epidermal growth factor receptor (EGFR) mutations and anaplastic
lymphoma kinase (ALK) gene recombinant NSCLC, but most NSCLC does not have
such mutations, so these targeted therapies are ineffective.
is a peptide vaccine formulation for the treatment of advanced NSCLC,
containing recombinant human epidermal growth factor (rEGF) linked to the
Neisseria meningitidis-derived recombinant immunogenic carrier protein
P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51. The vaccine
inhibits the growth of tumor cells and trophoblastic vessels by blocking
EGFR-mediated cell signaling through specific active immunity, and causes
apoptosis (programmed death) of tumor cells, thus achieving tumor suppression
and cancer treatment and improving patient survival and quality of life.
Figure1. A significant inverse correlation was observed between the anti-EGF
antibody titers and serum EGF concentration in patients treated with the
vaccine. (Xing, P.,
Animal tests and clinical studies have shown that the vaccine is immunogenic
and antitumor active, reduces EGF concentrations and increases anti-EGF
antibody titers, and is well tolerated. It has good efficacy against EGFR
over-expressed malignancies including lung, head, and neck cancers, ovarian
cancer, etc., especially for NSCLC.
As a specialized supplier and technical support solution provider in the
field of therapeutic proteins,
provides researchers with the most comprehensive range of therapeutic
protein products covering the widest possible range of disease research
areas. This includes, of course, support for non-small cell lung cancer
research, where we provide researchers with a recombinant non-small cell
lung cancer therapeutic vaccine (
) to assist researchers in advanced non-small cell lung cancer, head and
neck cancer, ovarian cancer, and other therapeutic studies. If you have
a research project in this area, please
our staff and we will be happy to provide you with high-end products and
professional technical support.
, (2018). “Therapeutic cancer vaccine: phase I clinical tolerance study
of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small
cell lung cancer.”
, 19: 14.